Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression.

@article{Polley2016SmallCL,
  title={Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression.},
  author={Eric C. Polley and Mark W Kunkel and David M Evans and Thomas E. Silvers and Rene M. Delosh and Julie Laudeman and Chad Ogle and Russell A Reinhart and Michael J. Selby and John Connelly and Erik Harris and Nicole Fer and Dmitriy Sonkin and Gurmeet Kaur and Anne P Monks and Shakun M. Malik and Joel Morris and Beverly A Teicher},
  journal={Journal of the National Cancer Institute},
  year={2016},
  volume={108 10}
}
BACKGROUND Small cell lung carcinoma (SCLC) is an aggressive, recalcitrant cancer, often metastatic at diagnosis and unresponsive to chemotherapy upon recurrence, thus it is challenging to treat. METHODS Sixty-three human SCLC lines and three NSCLC lines were screened for response to 103 US Food and Drug Administration-approved oncology agents and 423 investigational agents. The investigational agents library was a diverse set of small molecules that included multiple compounds targeting the… CONTINUE READING
Highly Cited
This paper has 38 citations. REVIEW CITATIONS
Recent Discussions
This paper has been referenced on Twitter 31 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 62 references

A multicenter, randomized, open-label, phase 2 study of carfilzomib with or without ARRY-520 (filanesib) in patients with advanced multiple myeloma

  • JA Zonder, NS Raje, EC Scott
  • J Clin Oncol
  • 2015
1 Excerpt

Similar Papers

Loading similar papers…